Navigation Links
Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
Date:5/28/2009

MOUNTAIN VIEW, Calif., May 28 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming (June 1, 2009) release of the Xfect(TM) and Xfect(TM) Stem transfection reagents. These novel transfection reagents are based on biodegradable nanoparticles that permit superior transfection efficiency of plasmid DNA into mammalian cells. For added ease of use, transfections can be carried out entirely in the presence of serum. Xfect shows high efficiency over a broad range of cell types, while Xfect Stem meets the highly specialized requirements for mouse embryonic stem cell transfections.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in developing technologies for gene delivery and expression. We identified a need for cost-effective, efficient and non-toxic transfection reagents, and responded with an innovative solution. We are pleased to announce the addition of Xfect transfection reagents to our wide range of established products, including our Lenti-X(TM) and Adeno-X(TM) viral delivery systems and vectors for Tet-On(R) Advanced- and ProteoTuner(TM)-based inducible expression."

Researchers recognize that effective, nontoxic DNA transfer is a vital first step in basic and applied research, including studies of gene regulation, protein expression, and function; the development of transgenic organisms; and therapeutic gene delivery. Clontech has a patent license from M.I.T. based on research by scientists at M.I.T. who screened more than 2,300 candidate polymers to identify novel biodegradable nanoparticles that facilitate exceptional transfection efficiency. Under the license, Clontech optimized two of the lead compounds from the screen to create the Xfect and Xfect Stem reagents.

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq(TM), LA Taq(TM), Titanium(TM), and Advantage(R) enzymes); RT enzymes and SMART(TM) library construction kits; the innovative In-Fusion(TM) cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information visit www.clontech.com.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.


'/>"/>
SOURCE Clontech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
2. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
4. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
5. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
8. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):